Literature DB >> 8709623

CD40 ligand triggers interleukin-6 mediated B cell differentiation.

M Urashima1, D Chauhan, M Hatziyanni, A Ogata, D Hollenbaugh, A Aruffo, K C Anderson.   

Abstract

Interleukin-6 (IL-6) is the major cytokine to date mediating antigen (Ag)- or mitogen-driven B cell differentiation. Recently, CD40 ligand (CD40L), with the co-stimulatory cytokines IL-4 and IL-10, has been shown to trigger immunoglobulin (Ig) secretion and class switching. In the present report, we have examined the role of IL-6 in mediating B cell differentiation and Ig secretion triggered with CD40L and/or these cytokines. Culture of splenic B cells with CD40L triggered (1) significant (5.4-fold) increases in IL-6 secretion; (2) differentiation, evidenced by sequential loss of B cell (CD20, CD21) and acquisition of plasma cell (CD38, PCA-1) surface antigens (Ags); and (3) Ig secretion. Interleukin-4 increased both IL-6 and IgG secretion stimulated by CD40L. Interleukin-10+ CD40L triggered 100-fold increments in IgG, IgA and IgM secretion, but IL-10 suppressed IL-6 secretion triggered with CD40L +/- IL-4. Exogenous IL-6 can further increase IgG secretion induced by CD40L + IL-10; moreover, the anti-IL-6 monoclonal antibody partially blocked IgG secretion triggered by CD40L +/- IL-4 or IL-10. Finally, IL-10 suppressed differentiation of B cells induced by CD40L. These studies suggest that CD40L augments Ig secretion in at least two mechanisms: by triggering IL-6 secretion and related differentiation, and by priming B cells for responsiveness to IL-10.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709623     DOI: 10.1016/0145-2126(95)00098-4

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  13 in total

Review 1.  Molecular link between cholesterol, cytokines and atherosclerosis.

Authors:  D Kaul
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

Review 2.  Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.

Authors:  Colin Phipps; Yunxin Chen; Sathish Gopalakrishnan; Daryl Tan
Journal:  Ther Adv Hematol       Date:  2015-06

3.  The 86-kD subunit of Ku autoantigen mediates homotypic and heterotypic adhesion of multiple myeloma cells.

Authors:  G Teoh; M Urashima; E A Greenfield; K A Nguyen; J F Lee; D Chauhan; A Ogata; S P Treon; K C Anderson
Journal:  J Clin Invest       Date:  1998-03-15       Impact factor: 14.808

4.  Optimized Protocols for In-Vitro T-Cell-Dependent and T-Cell-Independent Activation for B-Cell Differentiation Studies Using Limited Cells.

Authors:  Casper Marsman; Dorit Verhoeven; Jana Koers; Theo Rispens; Anja Ten Brinke; S Marieke van Ham; Taco W Kuijpers
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 5.  Bone marrow microenvironment and the identification of new targets for myeloma therapy.

Authors:  K Podar; D Chauhan; K C Anderson
Journal:  Leukemia       Date:  2008-10-09       Impact factor: 11.528

Review 6.  Targeted therapies in multiple myeloma.

Authors:  Efstathios Kastritis; Andreas Charidimou; Andreas Varkaris; Meletios A Dimopoulos
Journal:  Target Oncol       Date:  2009-01-17       Impact factor: 4.493

7.  TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation.

Authors:  Tony J Vanden Bush; Gail A Bishop
Journal:  Eur J Immunol       Date:  2008-02       Impact factor: 5.532

Review 8.  Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Authors:  Ivetta Danylesko; Katia Beider; Avichai Shimoni; Arnon Nagler
Journal:  Clin Dev Immunol       Date:  2012-05-10

9.  Disease progression in mice exposed to low-doses of aerosolized clinical isolates of Burkholderia pseudomallei.

Authors:  Sylvia R Trevino; Christopher P Klimko; Matthew C Reed; Michael J Aponte-Cuadrado; Melissa Hunter; Jennifer L Shoe; Joshua R Meyer; Jennifer L Dankmeyer; Sergei S Biryukov; Avery V Quirk; Kristen A Fritts; Steven J Kern; David P Fetterer; Lara J Kohler; Ronald G Toothman; Joel A Bozue; Christopher W Schellhase; Norman Kreiselmeier; Sharon P Daye; Susan L Welkos; Carl Soffler; Patricia L Worsham; David M Waag; Kei Amemiya; Christopher K Cote
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

Review 10.  Development of Novel Immunotherapies for Multiple Myeloma.

Authors:  Ensaf M Al-Hujaily; Robyn A A Oldham; Parameswaran Hari; Jeffrey A Medin
Journal:  Int J Mol Sci       Date:  2016-09-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.